加味六君子汤治疗慢性阻塞性肺疾病稳定期肺脾气虚证的疗效观察

发布时间：2018-02-11 21:16

本文关键词： 慢性阻塞性肺疾病稳定期加味六君子汤肺功能 CAT评分急性加重次数体重指数　出处：《湖南中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的:通过观察加味六君子汤对慢性阻塞性肺疾病稳定期肺脾气虚证患者的临床疗效及安全性,为临床治疗慢性阻塞性肺疾病稳定期提供更多的临床依据。方法:将符合纳入标准的60例慢性阻塞性肺疾病稳定期肺脾气虚证患者,采用随机数字表法分为两组,治疗组和对照组各30例。对照组采用西医常规治疗,给予低流量吸氧、噻托溴铵吸入及解痉平喘治疗;治疗组在对照组的基础上,加用加味六君子汤口服(每日一剂,早晚分服);疗程为12周,随访1年。观察两组患者治疗前后临床症状及体征、总体证候积分、肺功能、CAT评分、体重指数及急性加重次数的变化。结果:1.加味六君子汤治疗慢性阻塞性肺疾病稳定期肺脾气虚证患者,与对照组相比,在减轻症状(咳嗽、咳痰、喘息、纳呆、腹胀、自汗、易感冒等)和体征(Up音)的证候总积分上,总的治疗效果治疗组优于对照组(P0.05)。2.两组均能提高患者肺功能FEV1%,差异具有统计学意义(P0.05)。但治疗后治疗组与对照组组间比较肺功能FEV1%差异无统计学意义(P0.05)。3.加味六君子汤治疗慢阻肺稳定期肺脾气虚证患者,与对照组相比,可明显提高患者的体重指数,降低CAT评分,减少急性加重次数(P0.05)。结论:加味六君子汤可改善慢性阻塞性肺疾病稳定期肺脾气虚证患者总的临床症状和体征,提高总有效率;可改善患者肺功能FEV1%水平,改善情况与西药常规治疗无明显差异;可提高患者体重指数,改善慢性阻塞性肺疾病患者后期营养不良的状况,同时还可改善患者CAT评分,减少急性加重次数,提高患者生活质量,改善预后。
[Abstract]:Objective: to observe the clinical efficacy and safety of Jiawei Liujunzi decoction in the treatment of chronic obstructive pulmonary disease (COPD) with stable lung qi deficiency syndrome. Methods: 60 patients with chronic obstructive pulmonary disease at stable stage were divided into two groups by random digital table. The treatment group and the control group each had 30 cases. The control group was treated with routine western medicine, received low-flow oxygen inhalation, tiotropium bromide inhalation and antispasmolysis therapy, while the treatment group was treated with Jiawei Liujunzi decoction orally (one dose per day) on the basis of the control group. The course of treatment was 12 weeks and followed up for one year. The clinical symptoms and signs, total syndromes score, pulmonary function cat score before and after treatment were observed in both groups. Changes of body mass index and acute exacerbation times. Results: 1. Jiawei Liujunzi decoction was used to treat chronic obstructive pulmonary disease (COPD) patients with chronic obstructive pulmonary disease (COPD) during stable stage of deficiency of the lung. Compared with the control group, the patients were relieved of symptoms (cough, expectoration, wheezing, insufflation, abdominal distension, self-sweating). On the total score of syndromes and signs. The total therapeutic effect in the treatment group was better than that in the control group (P 0.05 .2.). Both groups could improve the pulmonary function of the patients with FEV1, the difference was statistically significant, but there was no significant difference in FEV1% between the treatment group and the control group after treatment. The decoction is used to treat the patients with deficiency of the lung in the stable period of chronic obstructive lung. Compared with the control group, it can significantly increase the body mass index, reduce the CAT score and reduce the acute exacerbation times (P0.050.Conclusion: the modified Liujunzi decoction can improve the total clinical symptoms and signs of chronic obstructive pulmonary disease patients with stable lung temper deficiency syndrome. Improving the total effective rate, improving the FEV1% level of pulmonary function of the patients, and improving the state of the patients with chronic obstructive pulmonary disease (COPD) were not significantly different from the routine treatment of western medicine, and could increase the body mass index of the patients and improve the malnutrition of the patients with chronic obstructive pulmonary disease (COPD) in the later stage. At the same time, it can improve the CAT score, reduce the times of acute exacerbation, improve the quality of life and improve the prognosis.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【参考文献】